This study demonstrates that synthesis neoepitopes for collagen type 3 and 6, but not the N-terminal pro-peptide of collagen type 1, distinguish individuals with IPF who have progressive disease from those with more stable disease.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a fatal condition with a dismal untreated prognosis and despite the approval of two anti-fibrotic therapies remains a major clinical challenge. At present there are no available measures for stratifying individuals with IPF to specific therapies nor, importantly, to determine response to therapy. Furthermore, although forced vital capacity (FVC) is accepted as a regulatory end-point in clinical trials, the relative insensitivity of physiological measures to change in fibrosis necessitates studies with a minimum duration of 52
weeks [1] . Therefore, there is an urgent need to identify biomarkers for various aspects of disease behaviour in IPF; particularly those that detect individuals at greater risk of progression and which stratify individuals into better defined endotypes (as a path to enabling effective targeting of therapies to individuals most likely to benefit).
Excessive extracellular matrix (ECM) deposition is central to the pathogenesis of IPF. The production, deposition and remodelling of collagen, a major component of ECM, is a dynamic process [ 2 ] . In healthy lung, there is a balance between degradation and synthesis of collagen and other ECM proteins
, which is disturbed in the lungs of individuals with fibrosis [ 3 -5 ] . During collagen turnover, distinct peptides are generated as by-products of both collagen breakdown and synthesis. The pro-peptide of pro-collagen is cleaved before collagen is incorporated into the matrix. This results in the release of unique fragments for each individual form of collagen [6] . Similarly, during degradation, specific metalloproteases (MMPs)
cleave collagen fibres revealing distinct neo-epitopes. Both synthesis peptides and cleavage neo-epitopes are released into the circulation and can be detected in the blood.
We have previously demonstrated, in subjects recruited to the PROFILE (Prospective Observation of Fibrosis in the Lung Clinical Endpoints) study, that serum levels of neoepitopes are higher in individuals with IPF when compared with healthy age-matched controls. Furthermore, we demonstrated that longitudinal changes in serum concentrations of several neo-epitopes track with progression of fibrosis and, by three months, can predict mortality in individuals with IPF [ 7 ] . In the current study, we assessed collagen formation markers for their prognostic utility in IPF in a separate cohort of individuals recruited into the PROFILE study. We also compared these synthesis markers to their collagen-equivalent degradation neoepitopes thus enabling assessment of the relationship between synthesis and degradation during IPF progression.
Methods:

Study design and participants
As previously described, the PROFILE study is a prospective, multicentre, observational cohort study that recruited individuals with IPF and fibrotic NSIP from two co-ordinating UK centres; Nottingham and Royal Brompton [7, 8] . Participants were enrolled if they had an incident diagnosis confirmed at multidisciplinary discussion according to international consensus guidelines [9] . The cohort of individuals used in the current study represents a sub-group of 145 participants from PROFILE; none of whom were included in the previous PROFILE study on neoepitopes [7] and all of whom had at least 1 year of follow up at the time neoepitope analyses were performed. A total of 50 physician-verified control participants without history of respiratory disease were recruited from primary care clinics. Samples from P a g e | 7 20 of these subjects were used in our earlier study [7] . All participants provided written informed consent. The PROFILE study is registered on ClinicalTrials.gov, numbers NCT01134822 and NCT01110694. For survival analyses, a censoring date of 1 st March 2016 was used.
Procedures
Patient samples
Serum samples collected from study participants at baseline, 1, 3, and 6 months, and a single serum sample from controls were stored at −80 °C until assayed. Studyspecific operating procedures for collection of the serum were used to ensure standardisation across both centres. Briefly, blood was collected with anticoagulant free, serum separation tubes, with coated silica as the clot activator (Becton Dickenson, Winnersh, UK). All samples were processed within 2h of collection.
Samples were allowed to clot at RT for 30min and serum was then isolated through centrifugation, and aliquoted before freezing.
Quantification of extracellular matrix related biochemical markers
Serum samples from patients were analysed using competitive ELISAs for the formation markers of type 1 collagen (P1NP)
, type 3 collagen (PRO-C3) ; was undertaken as previously described [ 7 ] . A single aliquot for each subject at each time-point was used for all assays to avoid repeated freeze/thaw of samples. Samples were analysed blinded to the associated clinical
data. Performance characteristics of the assays and non-standard abbreviations are described in the online data supplement, Table 1E .
Lung function measurements
Lung function measurements for forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) were performed on participants at baseline, 6 months and 12 months according to current ATS/ERS guidelines. Percent-predicted values are based on the European Coal and Steel Board reference equations using age and height at the baseline visit [17] .
Statistical Analysis
As previously described, 'progressive disease' was defined as ≥ 10% decline in FVC and/or death within 12 months. Missing lung function data were not imputed. Where no lung function data beyond baseline was available and the subject had not died within the relevant period, progression status was adjudicated by the responsible physician, after case note review and blinded to biomarker data at the time of adjudication. A total of 9 subjects were adjudicated for progression: 1 of these subjects were adjudicated as progression and 8 were adjudicated as stable.
In cases where biomarker data were below the lower limit of detection, values were imputed to be half the lower limit of detection. Associations between explanatory variables and endpoints were deemed to be significant at the 5% level. All statistical analyses were conducted with SAS (version 9.3) and were independently quality controlled by a second statistician.
Results
145
IPF participants recruited in the PROFILE study were assessed in the current analysis. As expected, participants were predominantly male (81%) with a mean age of 71.7 years (SD 7.7) and moderate lung function impairment; FVC 79.8 (SD 20.4) %predicted and DLco 48.2 (SD 17.9) %predicted. Subject demographics are presented in Table 1 . The 50 control subjects were 80% male with a mean age of 64.6 (SD 7.27).
At baseline, levels of PRO-C3 and PRO-C6 but not P1NP, were significantly elevated in individuals with IPF compared with healthy controls (Figure 1 ). To enable paired assessment of collagen synthesis and degradation, levels of neoepitopes previously linked with disease progression and survival in the PROFILE study [7] P a g e | 1 1
were measured. These included the three degradation neoepitopes which pair with the synthesis markers assessed; C1M (pairs with P1NP), C3M (PRO-C3) and C6M
(PRO-C6) and two additional neoepitopes from our previous study, CRPM and BGM.
In keeping with our previously presented data, C1M, C3M, C6M and CRPM neoepitopes were significantly elevated in the serum of subjects with IPF compared with controls at baseline ( Figure 1E ).
73 subjects had progressive disease whilst 71 had stable disease. Levels of both PRO-C3 and PRO-C6 were higher in individuals with progressive disease compared with those with stable disease at baseline and they remained consistently and significantly higher in individuals with progressive disease at all visits (1,3 and 6 months) (Figure 2 ). There were no significant differences between stable and progressive disease at any visit for P1NP (Figure 2 ).
Consistent with our previously reported findings, C1M, C3M, C6M and CRPM were also significantly higher in those with progressive disease compared with individuals with stable disease across all time-points (baseline, 1, 3 and 6 months) (see Figure   2E in the online data supplement).
When comparing ratios of synthesis and degradation markers P1NP:C1M was significantly lower in participants with progressive disease from 1 month onwards compared with stable disease, whilst PRO-C3:C3M was significantly lower in participants with stable disease at each time point compared with progressive disease ( Figure 3 ). There were no significant differences between stable and progressive disease at any timepoint for the ratio of PRO-C6:C6M ( Figure 3 ).
In an unadjusted univariate analysis, baseline concentrations of PRO-C3 (H.R. 1.49
(1.04-2.13), p = 0.030) and P1NP:C1M ratio (H.R. 0.67 (0.53-0.85), p=0.001) were predictive of survival ( Table 2) 
Discussion
Remodelling of extracellular matrix is pivotal to the development and progression of IPF and results in distinct alterations in collagen turnover. In the current study, we measured synthesis markers of three collagens important in the development of IPF;
namely collagen type-1 (P1NP), -3 (PRO-C3) and -6 (PRO-C6) [4, 18, 19] . Given
that fibrogenesis in IPF likely reflects an imbalance between synthesis and degradation of collagen, we also measured paired markers of degradation for the same collagens: type-1 (C1M), -3 (C3M) and -6 (C6M). For comparison with our prior observations [7] , we also measured degradation of the matrix molecule biglycan (BGM) and C reactive protein (CRPM). Our data demonstrate that synthesis markers for type-3 (PRO-C3) and-6 (PRO-C6) collagen are elevated in subjects with IPF compared with healthy controls and distinguished individuals with progressive disease, suggesting that these biomarkers may reflect underlying pathophysiology driving disease behaviour in IPF.
Collagen type-3, a fibrillar collagen, forms a major component of the lung interstitial extracellular matrix and is synthesised by activated fibroblasts [20] . Our findings support earlier studies demonstrating that synthesis of collagen type-3 is increased in IPF, with high levels of type-3 pro-collagen peptide reported in serum [18] and lavage fluid [21, 22] . In the case of collagen type-3, the synthesis neoepitope, PRO-C3, appears to be a better biomarker of progressive disease than the paired degradation biomarker, C3M. Interestingly, in subjects with more stable disease, the ratio of PRO-C3 to C3M is significantly lower; supporting the idea that synthesis, and increased turnover in general, may be reflective of active remodelling and disease progression.
Alongside collagen type-3, our data suggests that changes in collagen type-6 are also informative of disease behaviour in IPF and may be an important driver of fibrosis. Collagen type-6 filaments are an integral component found at the interface between the basement membrane and interstitial matrix of the lung, and act as an important network for attachment of basement membranes, collagen fibres and cells.
Our results support the importance of this collagen in the development of fibrosis.
Previous research suggests that collagen type-6 fragments have signalling properties during wound healing and fibrogenesis and may drive poorer outcomes in fibrotic diseases [23] . Compared with other collagens, type-6 collagen has been shown to be a potent inducer of the differentiation and activation of fibroblasts to highly synthetic myofibroblasts; a key pathway leading to the production of collagen and ECM proteins [24] . In addition, increased levels of serum collagen type-6 markers have been demonstrated to act as an early predictor of fibrosis in the liver [15] . This evidence, coupled with data from the current study, suggest that collagen type-6 may in itself be a driver of the fibrotic process, which in turn serves as a useful marker of IPF progression.
Intriguingly, whilst increases in collagen type-1 production are associated with TGFβ-activation of IPF fibroblasts [25] , and have been observed in IPF lung [26], we did not find elevated levels of collagen type 1 synthesis neoeptiopes in the serum of IPF subjects. However, collagen type-1 is also the predominant collagen found in bone and it has been estimated that 90% of the synthesis of this collagen measurable in serum is bone derived [27] . This may explain why there was no difference observed in P1NP, the measured marker of collagen type-1 synthesis, between IPF subjects and health controls and why differences were not seen between stable and progressive disease. In contrast to P1NP, the serum degradation marker of collagen type-1, C1M, does not measure bone-derived degradation as the epitope is denatured in bone by osteoclast-released cathepsin K [13] . This disparity in the pools of collagen type-1 being measured may account for the differences observed between this pair of synthesis and degradation neoepitopes.
Consistent with our previous study, baseline levels of C1M, C3M, C6M and CRPM were elevated in subjects with IPF compared with healthy controls. Furthermore, consistent with our prior observations, elevated CRPM distinguished progressive from stable disease from as early as one month after recruitment. In our previous study BGM, C1M, C3M and C6M were also different between individuals with stable and progressive IPF, but these differences only became significant at 6 months.
Interestingly, in the current study, the levels of C1M and C6M were significantly higher from 1 month onwards.
Rising levels over 3 months of matrix synthesis markers were not predictive of mortality. This is in distinct contrast with changing levels of the degradation markers CRPM, C1M, C3M and C6M; for each of these markers rising levels over 3 months identified subjects with an increased risk of death. The predictive value of these markers, as shown by the hazard ratios, was consistent with previous results
[ 7 ]
. A changing ratio over 3 months of synthesis and degradation markers for type 6 collagen, PRO-C6:C6M, was also predictive of mortality albeit less strongly than C6M alone. It is possible that the different characteristics of the synthesis and degradation markers may reflect the specific location of individual collagens within the fibrotic lung and their susceptibility to degradation as fibrosis progresses. We have shown that neoepitopes reflecting collagen synthesis and degradation in IPF are informative of prognosis, are able to distinguish progressive from nonprogressive disease and provide a 3-month read out of change in disease severity.
The utility of these observations is currently being tested in a randomised placebo control trial of nintedanib in individuals with IPF and preserved lung function (NCT02788474). If neo-epitopes can be shown to change with therapy, then these markers may be of use in shortening future clinical trials and for determining response to therapy in the clinic.
A major strength of our study is the prospective longitudinal design, which enabled blood sampling to be standardised and enabled collection of robust outcome data.
Furthermore, the PROFILE cohort is representative of real-world patients with IPF and includes many subjects who would not have been enrolled in clinical trials. As P a g e | 1 7 such our findings are more translatable to clinical practice than insights derived from clinical trial cohorts. The main weakness of this current study is that we undertook analysis of synthesis neoepitopes in a single cohort and did not adhere to a discovery-validation design. However, as this is the only longitudinal study that includes treatment-naive patients with multiple biological samples available that we are aware of, external replication of this study is not currently possible. We feel that this limitation is offset by our demonstration that degradation neo-epitopes behave in a way entirely consistent with our previous observations, which were performed in discovery, and validation sample sets. As such we believe that this confirmation of the usefulness of collagen degradation biomarkers provides indirect validation of our findings and supports our conclusions regarding the potential utility of collagen synthesis biomarkers.
In conclusion, this study demonstrates that collagen type-3 and -6 synthesis biomarkers are elevated in individuals with IPF compared with controls and differ in levels between stable and progressive disease, alongside collagen degradation neoepitopes. In addition, this study re-confirms the value of a panel of ECM degradation biomarkers that are predictive of disease progression and survival in IPF. This panel of biomarkers provides informative insights into matrix turnover and underlying pathophysiology driving disease progression, which may assist in the development of precision approaches to IPF treatment. Furthermore, the predictive prognostic value of change in these biomarkers is discernible within 3 months, providing much needed short-term measurements to assist the identification of atrisk IPF patients, which could be used to supplement physiological assessment to P a g e | Table 2 . Univariate analysis of overall survival in relation to baseline measures of collagen synthesis neoepitopes for collagen-type 1 (P1NP), -type 3 (PRO-C3) and -type 6 (PRO-C6), the ratio of collagen synthesis: degradation ratios for collagen-type 1 (P1NP:C1M), -type 3 (PRO-C3: C3M), and -type 6 (PRO-C6: C6M) and lung function measurements (% predicted FVC and % predicted DLCO) in IPF subjects. . . 
The data are expressed as mean hazard ratio (HR) with 95% CIs for all thresholds and represent the associated change in mortality risk based on a 2-fold increase in the explanatory value.
. 4 . K u l k a r n i T , O ' R e i l l y P , A n t o n y V B , G a g g a r A , T h a n n i c k a l V J . M a t r i x R e m o d e l i n g i n P u l m o n a r y F i b r o s i s a n d E m p h y s e m a . A m e r i c a n j o u r n a l o f r e s p i r a t o r y c e l l a n d m o l e c u l a r b i o l o g y 2 0 1 6 : J a . 5 . L e e m i n g D J , S a n d J M , N i e l s e n M J , G e n o v e s e F , M a r t i n e z F J , H o g a b o a m C M , H a n M K , K l i c k s t e i n L B , K a r s d a l M A . S e r o l o g i c a l i n v e s t i g a t i o n o f t h e cn J o u r n a l o f P h y s i o l o g y - L u n g C e l l u l a r a n d M o l e c u l a r P h y s i o l o g y 2 0 1 3 : 3 0 4 ( 1 1 ) : L 7 0 9 - L 7 2 1 . 7 . J e n k i n s R G , S i m p s o n J K , S a i n i G , B e n t l e y J H , R u s s e l l A - M , B r a y b r o o k e R , M o l y n e a u x P L , M c K e e v e r T M , W e l l s A U , F l y n n A . L o n g i t u d i n a l c h a n g e i n c o l l a g e n d e g r a d a t i o n b i o m a r k e r s i n i d i o p a t h i c p u l m o n aM a h e r T M , O b a l l a E , S i m p s o n J K , P o r t e J , H a b g o o d A , F a h y W A , F l y n n A , M o l y n e a u x P L , B r a y b r o o k e R , D i v y a t e j a H . A n e p i t h e l i a l b i o m a r k e r s i g n a t u r e f o r i d i o p a t h i c p u l m o n a r y f i b r o s i s : a n a n a l y s i s f r o m t h e m u l t i c e n t r e P R O F I L E c o h o r t s t u d y . T h e L a n c e t R e s p i r a t o r y M e d i c i n e 2 0 1 7 : 5 ( 1 2 ) : 9 4 6 - 9 5 5 . 9 . R a g h u G , C o l l a r d H R , E g a n J J , M a r t i n e z F J , B e h r J , B r o w n K K , C o l b y T V , C o r d i e r J - F F , F l a h e r t y K R , L a s k y J A , L y n c h D A , R y u J H , S w i g r i s J J , W e l l s A U , A n c o c h e a J , B o u r o s D , C a r v a l h o C , C o s t a b e l U , E b i n a M , H a n s e l l D M , J o h k o h T , K i m D S , K i n g T E , K o n d o h Y , M y e r s J , M ü l l e r N L , N i c h o l s o n A G , R i c h e l d i L , S e l m a n M , D u d d e n R F , G r i s s B S , P r o t z k o S L , S c h ü n e m a n n H J , F i b r o s i s A E J A C o I P . A n o f f i c i a l A T S / E R S / J R S / A L A T s t a t e m e n t : i d i o p a t h i c p u l m o n a r y f i b r o s i s : e v i d e n c e - b a s e d g u i d e l i n e s f o r d i a g n o s i s a n d m a n ag e m e n t . A m e r i c a n j o u r n a l o f r e s p i r a t o r y a n d c r i t i c a l c a r e m e d i c i n e 2 0 1 1 :1 8 3 ( 6 ) : 7 8 8 - 8 2 4 . 1 0 . L e e m i n g D J , L a r s e n D , Z h a n g C , H i Y , V e i d a l S , N i e l s e n R , H e n r i k s e n K , Z h e n g Q , B a r k h o l t V , R i i s B . E n z y m e - l i n k e d i m m u n o s o r b e n t s e r u m a s s a y s ( E L I S A s ) f o r r a t a n d h u m a n N - t e r m i n a l p r o - p e p t i d e o f cV e i d a l S S , K a r s d a l M A , V a s s i l i a d i s E , N a w r o c k i A , L a r s e n M R , N g u y e n Q H T , H ä g g l u n d P , L u o Y , Z h e n g Q4 1 9 5 - 4 2 0 0 . 2 1 . L o w R B , G i a n c o l a M S , K i n g T , C h a p i t i s J , V a c e k P , D a v i s G S . S e r u m a n d b r o n c h o a l v e o l a. K a r s d a l M , N i e l s e n S , L e e m i n g D , L a n g h o l m L , N i e l s e n M , M a n o n - J e n s e n T , S i e b u h r A , G u d m a n n N , R ø n n o w S , S a n d J . T h e g o o d a n d t h e b a d c o l l a g e n s o f f i b r o s i s - T h e i r r o l e i n s i g n a l i n g a n d o r g a n f u n c t i o n . A d v a n c e d d r u g d e l i v
